嘉应制药：因涉嫌信披违法违规 证监会对公司立案

Core Viewpoint - The company, Jiaying Pharmaceutical, is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, as per the Securities Law of the People's Republic of China and the Administrative Penalty Law of the People's Republic of China [1] Group 1 - The CSRC has decided to initiate a case against the company due to the alleged violations [1]